Reports
Semi-Solid Dosage Contract Manufacturing Market Analysis Report, 2026-2034
REPORT DETAILS
REPORT DETAILS
ABOUT THIS REPORT
Semi-Solid Dosage Contract Manufacturing Market Summary
The global semi-solid dosage contract manufacturing market is estimated around USD 17.40 Billion in 2025,with consistent growth anticipated during 2026–2034. This growth is driven by rising demand for topical pharmaceuticals, increasing pharmaceutical outsourcing activities, and expansion of advanced dermatology therapeutics. The market is projected to grow at a CAGR of 6.18% during the forecast period.
Market Statistics
Key Takeaways
- Creams segment dominated the market in 2025 due to broad dermatology and cosmetic pharmaceutical applications.
- Dermatology segment dominated the market in 2025 owing to rising prevalence of chronic skin disorders.
- Biotechnology companies segment is projected to grow at the fastest CAGR during the forecast period due to increasing clinical outsourcing activities.
- North America dominated the market in 2025 due to advanced pharmaceutical manufacturing infrastructure.
- Major companies operating in the market include Almac Group, Catalent, Contract Pharmaceuticals Limited, Fareva Group, Famar Health Care Services, and others.
Industry Dynamics
- Rising prevalence of chronic skin disorders continues to support market expansion.
- Increasing pharmaceutical outsourcing activities are accelerating CDMO demand.
- Regulatory complexity in topical formulations continues to challenge market growth.
- Strong growth is expected due to precision medicine, regenerative therapies, and organoid commercialization.
What is Semi-Solid Dosage Contract Manufacturing?
Semi-solid dosage contract manufacturing involves outsourced production services for pharmaceutical creams, gels, ointments, lotions, pastes, and transdermal formulations. These dosage forms are widely used in dermatology, pain management, wound care, and cosmetic therapeutics. Pharmaceutical companies are relying on contract manufacturers to enhance their production processes and ease their operational load.
The value chain consists of suppliers of raw materials, excipient suppliers, formulation developers, CDMOs, packagers, distributors, pharmaceutical firms, and healthcare providers. Services provided by CDMOs include development of formulations, analytical testing, manufacturing, filling, packaging, and regulatory services for topical pharmaceutical products.
Market growth is driven by increasing demand for dermatological drugs, outsourcing activity increases, and quick advancement in topical drugs delivery technology. The pharmaceutical industry keeps working on creating new partnerships to enhance scalability and speed up timeframes.
Drivers & Opportunities
Rising Prevalence of Dermatological Disorders: With the increasing incidence of conditions like psoriasis, eczema, acne, fungi and chronic wounds, the requirement for topical medications is growing globally. As per the American Academy of Dermatology, acne is prevalent among 50 million people in America annually, while atopic dermatitis affects about one out of ten Americans.The pharmaceutical companies are gearing up their output of creams, ointments, and gels in order to meet growing demands of the consumers.
Increasing Pharmaceutical Outsourcing: There is an increasing trend of outsourcing manufacturing of semi-solid dosage forms by pharmaceutical companies as a result of cost-cutting measures and the flexibility offered. The benefits of such partnerships include formulation knowledge, regulatory assistance, and scalable manufacturing. Biotech firms that have small or mid-sized operations continues outsourcing their manufacturing processes owing to the limited manufacturing capability in-house.
Restraints & Challenges
Stringent Regulatory Requirements: Semi-solid dosage forms need to adhere to regulatory standards related to sterility, microbial control, uniformity of viscosity, and packaging process. Compliance with GMP standards is expected to lead to higher costs for manufacturing organizations. Manufacturers with smaller facilities will continue struggling with quality assurance and regulation approval.
Opportunity
Growth of Advanced Drug Delivery Technologies: Advanced transdermal systems, nanoemulsion formulations, liposomal creams, and biologic-compatible topical therapeutics are creating major growth opportunities for specialized CDMOs. In May 2026, WuXi Biologics received GMP approval for its 18th drug product facility, expanding integrated biologics manufacturing capabilities. Pharmaceutical innovators continue investing in advanced formulation technologies to improve therapeutic performance.
Segmental Insights
The report provides a comprehensive analysis of the semi-solid dosage contract manufacturing market by product type, therapeutic application, and end user to pinpoint the key revenue generating and growth segments.
By Product Type
-
Creams
Creams held the largest market share in 2025 owing to their wide-ranging therapeutic applications in areas including dermatological care, antifungals, anti-inflammatories, and cosmetics. Cream formulations provide superior patient compliance and effective drug absorption characteristics. Pharmaceutical companies continue expanding cream-based product portfolios for prescription and OTC dermatology applications.
-
Gels
The gels segment is projected to grow at the fastest CAGR during the forecast period owing to increasing demand for non-greasy topical formulations and transdermal delivery systems. Gel-based therapeutics are witnessing higher adoption in pain management and cosmetic applications. Pharmaceutical innovators continue investing in hydrogel and advanced transdermal technologies.
By Therapeutic Application
-
Dermatology
Dermatology segment dominated the market in 2025 driven by increasing prevalence of chronic skin diseases and rising prescription demand for topical therapeutics. Dermatology products remain widely utilized across psoriasis, acne, eczema, and fungal infection treatments. Increasing development of biologic-compatible dermatology formulations continues to support segment expansion.
-
Pain Management
The pain management segment is projected to grow at the fastest CAGR during the forecast period due to increasing utilization of topical analgesics and transdermal therapies. Rising awareness regarding opioid-related side effects is supporting demand for alternative pain relief formulations. Pharmaceutical companies continue investing in advanced topical pain management products.
By End User
-
Pharmaceutical Companies
Pharmaceutical companies segment dominated the market in 2025 due to increasing outsourcing adoption among large pharmaceutical manufacturers. Companies continue utilizing CDMOs to improve manufacturing flexibility, reduce operational costs, and accelerate commercialization timelines. Rising development of topical therapeutics continues to support segment growth.
-
Biotechnology Companies
The biotechnology companies segment is projected to grow at the fastest CAGR during the forecast period owing to increasing outsourcing demand for clinical-stage manufacturing and small-batch production. Biotechnology firms continue relying on specialized CDMOs for formulation development and regulatory support services. Expansion of regenerative medicine and precision therapeutics is further supporting segment growth.
Regional Analysis
North America Semi-Solid Dosage Contract Manufacturing Market Insights
North America dominated the semi-solid dosage contract manufacturing market in 2025 due to advanced pharmaceutical infrastructure, strong outsourcing penetration, and increasing dermatology drug development activities. In December 2025, Bora Pharmaceuticals partnered with Corealis Pharma to provide comprehensive services in solid dosage form development and manufacturing from initial development to commercialization.The increasing level of investment in next-generation topical drug delivery systems has been instrumental in driving market growth in the region.
Europe Semi-Solid Dosage Contract Manufacturing Market Insights
Europe region held a considerable share in the market owing to its capabilities in pharmaceutical manufacturing, stringent regulations, and escalating demand for dermatology therapeutics. Almirall reported strong growth in its European dermatology business, with net sales rising 24.2% year-on-year to approximately USD 337 million.Increasing investments in GMP-certified manufacturing facilities continue supporting regional market expansion.
Asia Pacific Semi-Solid Dosage Contract Manufacturing Market Insights
Asia Pacific is projected to grow at the fastest CAGR during the forecast period owing to lower manufacturing costs, skilled labor availability, and expanding pharmaceutical infrastructure. According to the Indian Ministry of Chemicals and Fertilizers, India’s pharmaceutical market is projected to grow from USD 60 billion to USD 130 billion by 2030, supported by over 3,000 companies and 10,500 manufacturing units.Government support for pharmaceutical manufacturing expansion and increasing CDMO investments continue driving regional growth.
Competitive Landscape & Key Players
The semi-solid dosage contract manufacturing market is moderately fragmented due to the presence of global CDMOs and regional pharmaceutical manufacturing providers. The key competitive determinants include regulatory compliance, formulation knowledge, manufacturing capability, pricing, and quality of the product. Companies continue focusing on strategic partnerships, capacity expansion, technology investments, and acquisitions to strengthen market positioning.
The leading players involved in the industry include Almac Group, Catalent, Contract Pharmaceuticals Limited, Fareva Group, Famar Health Care Services, Jubilant HollisterStier, Kindeva Drug Delivery, Lonza, MedPharm, Piramal Pharma Solutions, Recipharm, Vetter Pharma, and others.
Premium Insights
Integrated CDMO Service Expansion
The future competitive landscape is expected to favor CDMOs offering integrated services from formulation development to commercial manufacturing. The pharmaceutical companies are giving preference to the outsourcing partners that offer the complete manufacturing as well as the regulatory capabilities.
AI-Enabled Manufacturing Technologies
The companies are making investments in manufacturing analysis systems based on artificial intelligence, automation of manufacturing processes, and quality management tools. This is expected to bring improvements in manufacturing efficiencies.
Personalized and Biologic-Compatible Therapeutics
Personalized topical products and semi-solid formulations that can be easily integrated into biology are anticipated to drive future market trends. The rise in regenerative and precision medicine products creates more opportunities for CDMOs.
Emerging Smart Manufacturing Solutions
Innovative technologies like continuous manufacturing, digital twin modeling, and smart packaging is expected to serve as important differentiating factors in future global manufacturers. Companies adopting advanced manufacturing infrastructure are likely to strengthen long-term market competitiveness.
Key Players
- Almac Group
- Catalent
- Contract Pharmaceuticals Limited
- Fareva Group
- Famar Health Care Services
- Jubilant HollisterStier
- Kindeva Drug Delivery
- Lonza
- MedPharm
- Piramal Pharma Solutions
- Recipharm
- Vetter Pharma
Industry Developments
- April 2026: CPL announced to strengthen its topical drug development through advanced semi-solid formulation expertise, analytical testing, and scalable GMP manufacturing capabilities. [source: cplltd.com]
- January 2025: Otsuka Pharmaceutical announced initiatives to strengthen healthcare innovation and improve patient care through advanced medical and pharmaceutical developments. [source: www.otsukakj.jp]
Semi-Solid Dosage Contract Manufacturing Market Segmentation
By Product Type Outlook (Revenue, USD Billion, 2021-2034)
- Creams
- Gels
- Ointments
- Lotions
- Pastes
By Therapeutic Application Outlook (Revenue, USD Billion, 2021-2034)
- Dermatology
- Pain Management
- Wound Care
- Cosmetic Therapeutics
- Others
By End User Outlook (Revenue, USD Billion, 2021-2034)
- Pharmaceutical Companies
- Biotechnology Companies
- Cosmetic Companies
- Research Organizations
By Regional Outlook (Revenue, USD Billion, 2021-2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Semi-Solid Dosage Contract Manufacturing Market Report Scope
| Report Attributes | Details |
| Market Size in 2025 | USD 21.04 Billion |
| Market Size in 2026 | USD 23.38 Billion |
| Revenue Forecast by 2034 | USD 55.39 Billion |
| CAGR | 11.35% from 2026 to 2034 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2034 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Industry Trends |
| Segments Covered |
|
| Regional Scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The global market size was valued at USD 21.04 Billion in 2025 and is projected to grow to USD 55.39 Billion by 2034.
North America dominated the market in 2025 due to advanced pharmaceutical outsourcing infrastructure.
Major applications include dermatology, pain management, wound care, and cosmetic therapeutics.
A few of the key players in the market are Almac Group, Catalent, Contract Pharmaceuticals Limited, Fareva Group, Famar Health Care Services, Jubilant HollisterStier, Kindeva Drug Delivery, Lonza, MedPharm, Piramal Pharma Solutions, Recipharm, Vetter Pharma, and others.
Market growth is driven by increasing pharmaceutical outsourcing, rising skin disease prevalence, and advancements in topical drug delivery technologies.
The creams segment dominated the market in 2025 due to broad dermatology applications.
Strong growth is expected due to precision medicine, regenerative therapies, and organoid commercialization.
Download Sample Report of Semi-Solid Dosage Contract Manufacturing Market
Please fill out the form to request a customized copy of the research report.
